{"id":196455,"date":"2024-09-20T17:23:39","date_gmt":"2024-09-20T22:23:39","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/09\/fda-approves-rybrevant-for-advanced-lung-cancer"},"modified":"2024-09-20T17:23:39","modified_gmt":"2024-09-20T22:23:39","slug":"fda-approves-rybrevant-for-advanced-lung-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/09\/fda-approves-rybrevant-for-advanced-lung-cancer","title":{"rendered":"FDA approves Rybrevant for advanced lung cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/fda-approves-rybrevant-for-advanced-lung-cancer3.jpg\"><\/a><\/p>\n<p>The FDA approved amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to the agent\u2019s manufacturer.<\/p>\n<p>The indication applies to adults with <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/hematology-oncology\/20240917\/patritumab-deruxtecan-extends-pfs-vs-chemotherapy-in-advanced-nonsmall-cell-lung-cancer\" id=\"rId12\" target=\"_blank\">locally advanced or metastatic NSCLC<\/a> with <em>EGFR<\/em> exon 19 deletions or L858R substitution mutations whose disease progressed on or following treatment with an EGFR tyrosine kinase inhibitor.<\/p>\n<p><a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/hematology-oncology\/20230906\/rybrevant-extends-pfs-in-egfrmutant-lung-cancer\" id=\"rId13\" target=\"_blank\">Amivantamab-vmjw (Rybrevant, Janssen)<\/a> is an EGFR and mesenchymal epithelial transition (MET) factor bispecific antibody that targets activating and resistant <em>EGFR<\/em> and <em>MET<\/em> mutations and amplifications.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA approved amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to the agent\u2019s manufacturer. The indication applies to adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R substitution mutations whose disease progressed on or following treatment with an EGFR [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-196455","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/196455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=196455"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/196455\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=196455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=196455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=196455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}